Press Release
27 August 2021
Immunicum Announces Participation in Multiple Upcoming Industry and Investor Events in September and October
Immunicum AB (publ) today announced that it will participate in the following upcoming industry events and investor conferences in the period until 31 October.
• 6th CAR-TCR Summit, August 30 – September 2, 2021
Alex Karlsson-Parra, Chief Scientific Officer at Immunicum will be an expert speaker in a workshop at the CAR-TCR summit on 30 August 2021. He will present the potential use of Immunicum’s ilixadencel and DCOne® platforms to improve the quality of T cells for CAR-T and other adoptive T cell-based cancer therapies.
• Pareto Securities’ 12th Annual Healthcare Conference, September 1 – 2, 2021
Erik Manting, Chief Executive Officer at Immunicum will present at the investor conference.
• SACHS 21st Annual Biotech in Europe Forum, October 7 – 8, 2021
Erik Manting, Chief Executive Officer at Immunicum, will present at the investor conference.
• ESGO 22nd European Congress on Gynaecological Oncology, October 23 – 25, 2021
Immunicum will participate and present preclinical data on the use of its cancer relapse vaccine DCP-001 in ovarian cancer.
• Neoantigen Based Therapies Summit, October 26 – 28, 2021
Alex Karlsson-Parra, Chief Scientific Officer at Immunicum will present the combination potential of Immunicum’s ilixadencel and DCOne® platforms in relation to cancer neoantigen-based therapeutic approaches.
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: ir@immunicum.com
INVESTOR RELATIONS
Kristina Windrup Olander
Spikinc AB
Telephone: +46 72 545 34 74
E-mail: ir@immunicum.com
MEDIA RELATIONS
Sophia Hergenhan & Jacob Verghese
Trophic Communications
Telephone: +49 160 90816161
E-mail: immu@trophic.eu
ABOUT IMMUNICUM AB (publ)
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachment
